ABSTRACT
The collection and examination method of vaginal smears is the standard for the determination of ovulation or phases of the estrous cycle of rodents used in research. However, this method is time consuming and may not be amenable to continual monitoring of a large number of animals. Infrared thermography has recently emerged as a noninvasive technique that requires relatively little handling of animals. The body temperature of rodents has been shown to correlate with the ocular surface temperature. This study aimed to evaluate the use of thermographic monitoring of the ocular surface for the identification of estrus in rats. Vaginal smears were collected from female Wistar rats (n = 22) for 14 consecutive days. Core body temperature was estimated by measuring ocular surface temperature using a thermal camera; vaginal temperature was measured using a digital thermometer. Average temperatures were calculated for each rat for each phase of the estrous cycle. The highest core body and vaginal temperature were measured during the estrus phase (37.2 ± 0.6 °C and 37.7 ± 0.6 °C, respectively). The temperatures then fell as the rat entered the diestrus phase (36.8 ± 0.5 °C and 37 ± 0.5 °C). The core body temperature was positively correlated with vaginal temperature (r = 0.697, P < 0.001). In conclusion, thermography is a less invasive method of determining estrus in rats as compared with vaginal smear collection. However, thermography is less accurate and requires at least a 12-d period of measurement.
ABSTRACT
Rheumatoid arthritis (RA) is associated with high cardiovascular mortality. It is not clear whether the metabolic consequences of chronic inflammation are involved. Biological disease-modifying anti-rheumatic drugs (bDMARDs) are highly efficient in the treatment of inflammation in RA. In this study, we aimed to describe the metabolic effects of anti-TNF-α treatment in RA patients. The clinical status of 16 patients was assessed using disease activity score-28 (DAS28) and C-reactive protein (CRP). Plasma samples were collected before treatment with anti-TNF-α treatment as well as after three and six months of treatment. Markers of lipid and glucose metabolism, as well as renal biomarkers, were assessed using standard biochemistry. ELISA was used for the quantification of insulin, leptin, and adiponectin. Although fasting insulin decreased by 14% at the end of the study, most of the analyzed parameters did not show any statistically or clinically significant dynamics. The exception was total bilirubin and cholesterol, which increased by 53% and 14%, respectively, after six months of treatment with anti-TNF-α treatment. Anti-TNF-α treatment did not induce major metabolic changes despite the strong anti-inflammatory and clinical symptoms of RA. Further studies will show whether longer observations are required for the detection of the metabolic effects of the anti-inflammatory treatment. Additional research is needed to understand the observed effect of bilirubin as an important endogenous antioxidant.
